Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity

K.P. Kim,Geundoo Jang,Yeon-Sik Hong,H.E. Lim,K.S. Bae,Hyung-O Kim,S. Lee,Shin Jg,Jason H. Lee,Min-Hee Ryu,Hye-Sook Chang,Yoon-Koo Kang,Tae-Won Kim

Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity

2011

K.P. Kim
Geundoo Jang
Yeon-Sik Hong
H.E. Lim
K.S. Bae
Hyung-O Kim
S. Lee
Shin Jg
Jason H. Lee
Min-Hee Ryu
Hye-Sook Chang
Yoon-Koo Kang
Tae-Won Kim

Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity

Keywords:

Phases of clinical research
Cancer
Immunology
Bile duct cancer
Metastasis
Oxaliplatin
Medicine
Biliary tract
Pharmacokinetics
Biliary tract neoplasm
Chemotherapy
Tegafur
Tolerability
Neutropenia

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations